Predicting disease progression more effectively and developing individual therapies

The KKNMS is looking in some of its study centers for participants for a long-term study which will investigate which patients benefit from certain forms of treatment in the early stages of MS. This so-called MS cohort study with 1000 participants is planned for a duration of 10 years. A total of 18 MS centers from all over Germany are involved in this research project.

If you would like to participate in this study, you must meet the following criteria:


Inclusion criteria:

  • At least 18 years of age
  • Clinically isolated syndrome (CIS) within the past 6 months or early relapsing- remitting multiple sclerosis for at the most 2 years after initial symptoms
  • No previous long-term treatment for MS

Exclusion criteria:

  • Any factors which argue against MRT examinations (i.e. intolerance to contrast medium, cardiac pacemaker, claustrophobia, etc.)
  • Primary progressive MS

If you meet all criteria, we look forward to your contacting us any time.

Participating MS centers

Heinrich-Heine-Universität Düsseldorf

Neurologische Klinik

2.2 Comparing and Contrasting Multiple Sclerosis and Neuromyelitis optica Spectrum Disorders (NEMOS)
PI: Prof. Dr. Orhan Aktas

Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
PIs Studienzentrum: Prof. Dr. Hans-Peter-Hartung und Prof. Dr. Orhan Aktas

Johannes-Gutenberg-Universität Mainz

Klinik für Neurologie

3.2 Brain network patterns as prognostic and therapy response markers in multiple sclerosis (MSNetworks)
PI: Prof. Dr. Frauke Zipp
Co-Pis: Prof. Dr. Sergiu Groppa, Dr. Felix Lüssi

Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
PI Studienzentrum: Prof. Dr. med. Frauke Zipp

Klinikum Augsburg

Neurologische Klinik und klinische Neurophysiologie

Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
Assoziiertes Mitglied: Dr. Antonios Bayas

Ludwig-Maximilians-Universität München

Institut für Klinische Neuroimmunologie

2.2 Comparing and Contrasting Multiple Sclerosis and Neuromyelitis optica Spectrum Disorders (NEMOS)
Co-PI: Prof. Dr. Tania Kümpfel

3.4 B-cells and antibody profiles (BIginMS)
PI: Prof. Dr. Edgar Meinl
Co-PI: Prof. Dr. Reinhard Hohlfeld

5.5 Improved assessment of disease phenotypes in multiple sclerosis models (PhenoModel)
PI: Prof. Dr. Martin Kerschensteiner

Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
PI Studienzentrum: Prof. Dr. med. Reinhard Hohlfeld

Max-Planck-Institut für Psychiatrie

1.5 Biostatistical support and data analysis (Biostat)
Co-PI: Prof. Dr. Bertram Müller-Myhsok

4.2 Genetic determinants of MRI changes in MS (Gene-MRI)
Co-PI: Prof. Dr. Bertram Müller-Myhsok

4.3 Genetic determinants of cerebrospinal fluid parameters in multiple sclerosis (Gene-CSF)
Co-PI: Prof. Dr. Bertram Müller-Myhsok

Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
PI Studienzentrum: Prof. Dr. Frank Weber

Medizinische Hochschule Hannover

Neurologische Klinik

2.2 Comparing and Contrasting Multiple Sclerosis and Neuromyelitis optica Spectrum Disorders (NEMOS)
Co-PI: PD Dr. Corinna Trebst

Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
PI Studienzentrum: Prof. Dr. Martin Stangel

Philipps-Universität Marburg

Central Information Office:

1.2 IT platform for the Competence Network Multiple Sclerosis (CoreUnitIT)
PI: Dr. Gisela Antony

2.1 Prospective cohort study in clinically isolated syndrome and early multiple sclerosis (KKNMS-Kohorte)
Co-PI: Dr. Gisela Antony

2.2 Comparing and Contrasting Multiple Sclerosis and Neuromyelitis optica Spectrum Disorders (NEMOS)
Co-PI: Dr. Gisela Antony

2.4 Extension and internationalization of REGIMS, an immune therapy register for the improvement of drug safety and treatment of patients with MS (REGIMS)
Co-PI: Dr. Gisela Antony

Universitätsklinikum Marburg, Klinik für Neurologie:

Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
PI Studienzentrum: PD Dr. Björn Tackenberg

Ruhr-Universität Bochum

Neurologische Universitätsklinik:

2.1 Prospective cohort study in clinically isolated syndrome and early multiple sclerosis (KKNMS-Kohorte)
PI: Prof. Dr. Ralf Gold
Co-PI: Dr. Anke Salmen

2.2 Comparing and Contrasting Multiple Sclerosis and Neuromyelitis optica Spectrum Disorders (NEMOS)
Co-PIs: PD Dr. Kerstin Hellwig, Prof. Dr. Ingo Kleiter

Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
PI Studienzentrum: Prof. Dr. med. Ralf Gold

Institut für diagnostische und interventionelle Radiologie und Nuklearmedizin:

1.6 MRI Quality and Standards (MuSIQC)
PI: Prof. Dr. Carsten Lukas

4.2 Genetic determinants of MRI changes in MS (Gene-MRI)
Co-PI: Prof. Dr. Carsten Lukas

Technische Universität München

Klinikum rechts der Isar
Klinik und Poliklinik für Neurologie

1.1 Central Network Coordination (CoreOffice)
PI: Sandra Hanschke

1.3 Biomaterial Bank of the KKNMS (Biobank)
PI: Prof. Dr. med. Bernhard Hemmer

4.2 Genetic determinants of MRI changes in MS (Gene-MRI)
PI: Prof. Dr. Mark Mühlau

4.3 Genetic determinants of cerebrospinal fluid parameters in multiple sclerosis (Gene-CSF)
PI: Prof. Dr. Bernhard Hemmer
Co-PIs: Dr. Dorothea Buck, Dr. Markus Kowarik

5.2 Interplay of antigen specific T cells and B cells in mouse models of neuromyelitis optica (T-B in NMO)
PI: Prof. Dr. Thomas Korn

Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
PI Studienzentrum: Prof. Dr. med. Bernhard Hemmer

Universität Heidelberg

Neurologische Klinik
Sektion Molekulare Neuroimmunologie

2.2 Comparing and Contrasting Multiple Sclerosis and Neuromyelitis optica Spectrum Disorders (NEMOS)
Co-PI: Prof. Dr. Brigitte Wildemann

3.5 Signatures of immune reprogramming in anti-CD52 therapy of MS: markers for risk stratification and treatment response (ProgramMS)
Co-PI: Prof. Dr. Brigitte Wildemann

3.6 Predictive markers of imminent recurrence or rebound disease activity in MS patients switching immunotherapy (ReboundMS)
PI: Prof. Dr. Brigitte Wildemann
Co-PI: Dr. Jürgen Haas

Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
PI Studienzentrum: Prof. Dr. med. Brigitte Wildemann

Universität Ulm

Neurologische Universitätsklinik

3.6 Predictive markers of imminent recurrence or rebound disease activity in MS patients switching immunotherapy (ReboundMS)
Co-PI: Prof. Dr. Hayrettin Tumani

4.3 Genetic determinants of cerebrospinal fluid parameters in multiple sclerosis (Gene-CSF)
Co-PI: Prof. Dr. Hayrettin Tumani

Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
PI Studienzentrum: Prof. Dr. med. Hayrettin Tumani

Universitätsklinikum Carl Gustav Carus an der TU Dresden

Klinik und Poliklinik für Neurologie

Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
PI Studienzentrum: Prof. Dr. Tjalf Ziemssen

Universitätsklinikum Charité

Institut für Neuroimmunologie

Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
PI Studienzentrum: Prof. Dr. Friedemann Paul

Universitätsklinikum Erlangen

Neurologische Klinik
Neuroimmunologie

Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
PI Studienzentrum: Prof. Dr. Ralf Linker

Universitätsklinikum Hamburg-Eppendorf

Molekulare Neurobiologie Hamburg (ZMNH)
Institut für Neuroimmunologie und Multiple Sklerose (INIMS)

2.2 Comparing and Contrasting Multiple Sclerosis and Neuromyelitis optica Spectrum Disorders (NEMOS)
Co-PI: Dr. Jan-Patrick Stellmann

5.3 Modeling CD8+ T cell responses in multiple sclerosis (CD8Model)
PI: Prof. Dr. Manuel Friese

Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
PI Studienzentrum: Prof. Dr. med. Christoph Heesen

Universitätsklinikum Leipzig

Klinik und Poliklinik für Neurologie

Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
PI Studienzentrum: PD Dr. Florian Then Bergh

Universitätsklinikum Rostock

Klinik für Neurologie und Poliklinik

Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
PI Studienzentrum: Prof. Dr. Uwe Zettl

Universitätsklinikum Tübingen

Allgemeine Neurologie

Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
PI Studienzentrum: Prof. Dr. Ulf Ziemann

Westfälische Wilhelms-Universität Münster

Universitätsklinikum – Department für Neurologie:

1.3 Biomaterial Bank of the KKNMS (Biobank)
Co-PI: Prof. Dr. Heinz Wiendl

3.1 Multi-parameter immune cell-profiling: identification of biosignatures to understand heterogeneity, prognosis and treatment response factors (ImmuneMS)
PI: Prof. Dr. Heinz Wiendl
Co-PIs: PD Dr. Luisa Klotz; Dr. Catharina Groß

3.5 Signatures of immune reprogramming in anti-CD52 therapy of MS: markers for risk stratification and treatment response (ProgramMS)
PI: Prof. Dr. Dr. Sven Meuth
Co-PIs: Prof. Dr. Heinz Wiendl, Dr. Tobias Ruck

3.6 Predictive markers of imminent recurrence or rebound disease activity in MS patients switching immunotherapy (ReboundMS)
Co-PIs: Prof. Dr. Heinz Wiendl, Prof. Dr. Dr. Sven Meuth

Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
PI Studienzentrum: Prof. Dr. med. Heinz Wiendl

Institut für Epidemiologie und Sozialmedizin:

2.4 Extension and internationalization of REGIMS, an immune therapy register for the improvement of drug safety and treatment of patients with MS (REGIMS)
PI: Prof. Dr. Klaus Berger

MS-Kohortenstudie